Skip to main content

Advertisement

SpringerLink
Log in

Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Empirical antifungal therapy is widely used in high-risk neutropenic hematology patients with fever persisting for more than 4 days. This clinical trial assessed whether immediate empirical therapy with voriconazole could lower the rates of invasive fungal infections (IFIs) compared with this approach. In a double-blind, placebo-controlled, multicenter study, patients with acute leukemia undergoing chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT) recipients were randomized to broad-spectrum antibacterial therapy plus voriconazole (immediate) or placebo (deferred) after the onset of neutropenic fever. If fever persisted for 96 h, patients were switched to open-label intravenous voriconazole; oral treatment was permitted after 96 h. The primary endpoint was the rate of proven/probable IFIs between Days 2 and 28 after fever onset in the modified intent-to-treat (mITT) complete-case population. One hundred and forty-seven patients were randomized to immediate (n = 81) or deferred (n = 66) voriconazole. In the mITT population, six patients in the immediate group and nine in the deferred group developed proven/probable IFI between Days 2 and 28 (p = 0.258). The safety profiles were similar in both groups. While immediate empirical therapy with voriconazole appears to be safe in febrile neutropenic high-risk patients, it was not associated with a significant reduction in IFIs compared with therapy deferred for 96 h after fever onset.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. Disclaimer: voriconazole is not specifically licensed for empirical antifungal therapy in febrile neutropenic patients.

References

  1. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, de Pauw BE, Rubin RH (2007) Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44:373–379

    Article  PubMed  Google Scholar 

  2. Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–3645

    Article  PubMed  CAS  Google Scholar 

  3. Kumar A (2009) Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin 25:733–751, viii

    Article  PubMed  CAS  Google Scholar 

  4. Garey KW, Turpin RS, Bearden DT, Pai MP, Suda KJ (2007) Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents 29:557–562

    Article  PubMed  CAS  Google Scholar 

  5. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Dellow E, Herbrecht R, Donnelly JP (2011) Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 54:e449–e455

    Article  PubMed  Google Scholar 

  6. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 91:986–989

    PubMed  Google Scholar 

  7. Kume H, Yamazaki T, Togano T, Abe M, Tanuma H, Kawana S, Okudaira M (2011) Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in annual of pathological autopsy cases in Japan. Med Mycol J 52:117–127

    Article  PubMed  Google Scholar 

  8. Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, Mildenberger P, Thelen M (1999) Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 17:796–805

    PubMed  CAS  Google Scholar 

  9. Maschmeyer G, Beinert T, Buchheidt D, Cornely OA, Einsele H, Heinz W, Heussel CP, Kahl C, Kiehl M, Lorenz J, Hof H, Mattiuzzi G (2009) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 45:2462–2472

    Article  PubMed  CAS  Google Scholar 

  10. Pfeiffer CD, Fine JP, Safdar N (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42:1417–1427

    Article  PubMed  CAS  Google Scholar 

  11. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Amé S, Lutz P, Dufour P, Bergerat JP, Candolfi E (2002) Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20:1898–1906

    Article  PubMed  Google Scholar 

  12. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604–1610

    Article  PubMed  CAS  Google Scholar 

  13. Hebart H, Löffler J, Reitze H, Engel A, Schumacher U, Klingebiel T, Bader P, Böhme A, Martin H, Bunjes D, Kern WV, Kanz L, Einsele H (2000) Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol 111:635–640

    Article  PubMed  CAS  Google Scholar 

  14. Buchheidt D, Baust C, Skladny H, Baldus M, Bräuninger S, Hehlmann R (2002) Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 116:803–811

    Article  PubMed  CAS  Google Scholar 

  15. Link H, Böhme A, Cornely OA, Höffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW; Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO); Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society) (2003) Antimicrobial therapy of unexplained fever in neutropenic patients—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 82(Suppl 2):S105–S117

    Article  PubMed  CAS  Google Scholar 

  16. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, Gachot B, Heinz WJ, Lass-Flörl C, Ribaud P, Thiebaut A, Cordonnier C; Third European Conference on Infections in Leukemia (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update. Bone Marrow Transplant 46:709–718

    Article  PubMed  CAS  Google Scholar 

  17. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764–771

    Article  PubMed  CAS  Google Scholar 

  18. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234

    Article  PubMed  CAS  Google Scholar 

  19. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402

    Article  PubMed  CAS  Google Scholar 

  20. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360

    Article  PubMed  CAS  Google Scholar 

  21. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242–1250

    Article  PubMed  CAS  Google Scholar 

  22. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhédin N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48:1042–1051

    Article  PubMed  CAS  Google Scholar 

  23. Tan BH, Low JG, Chlebicka NL, Kurup A, Cheah FK, Lin RT, Goh YT, Wong GC (2011) Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis 15:e350–e356

    Article  PubMed  CAS  Google Scholar 

  24. Schiel X, Link H, Maschmeyer G, Glass B, Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Ostermann H, Hentrich M (2006) A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 34:118–126

    Article  PubMed  CAS  Google Scholar 

  25. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, Hebart H, Heinz W, Junghanss C, Karthaus M, Krüger W, Krug U, Kubin T, Penack O, Reichert D, Reuter S, Silling G, Südhoff T, Ullmann AJ, Maschmeyer G (2009) Treatment of invasive fungal infections in cancer patients—recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 88:97–110

    Article  PubMed  Google Scholar 

  26. Thursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD, Gilroy N, Chu J, Shaw DR (2008) Recommendations for the treatment of established fungal infections. Intern Med J 38:496–520

    Article  PubMed  CAS  Google Scholar 

  27. Herbrecht R, Flückiger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C (2007) Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 5:49–59

    Article  CAS  Google Scholar 

  28. Hebart H, Löffler J, Meisner C, Serey F, Schmidt D, Böhme A, Martin H, Engel A, Bunje D, Kern WV, Schumacher U, Kanz L, Einsele H (2000) Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 181:1713–1719

    Article  PubMed  CAS  Google Scholar 

  29. Löffler J, Henke N, Hebart H, Schmidt D, Hagmeyer L, Schumacher U, Einsele H (2000) Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol 38:586–590

    Google Scholar 

  30. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359

    Article  PubMed  CAS  Google Scholar 

  31. Ruhnke M, Böhme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, Enzensberger R, Hebart H, Heussel CP, Horger M, Hof H, Karthaus M, Krüger W, Maschmeyer G, Penack O, Ritter J, Schwartz S; Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (2012) Diagnosis of invasive fungal infections in hematology and oncology—guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 23:823–833

    Article  PubMed  CAS  Google Scholar 

  32. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14

    Article  PubMed  CAS  Google Scholar 

  33. de Pauw BE (2005) Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 41:1251–1253

    Article  PubMed  Google Scholar 

  34. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K; Itraconazole Neutropenia Study Group (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135:412–422

    PubMed  CAS  Google Scholar 

  35. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068–1075

    PubMed  Google Scholar 

  36. Lafaurie M, Lapalu J, Raffoux E, Breton B, Lacroix C, Socié G, Porcher R, Ribaud P, Touratier S, Molina JM (2010) High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 16:1191–1196

    Article  PubMed  CAS  Google Scholar 

  37. White PL, Bretagne S, Klingspor L, Melchers WJ, McCulloch E, Schulz B, Finnstrom N, Mengoli C, Barnes RA, Donnelly JP, Loeffler J; European Aspergillus PCR Initiative (2010) Aspergillus PCR: one step closer to standardization. J Clin Microbiol 48:1231–1240

    Article  PubMed  CAS  Google Scholar 

  38. Bennett JE, Powers J, Walsh T, Viscoli C, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, Lee J, Pappas P, Rex J, Verweij P (2003) Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 36(Suppl 3):S117–S122

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was sponsored by Pfizer Inc.

The authors would like to thank Peter Cooper and Fiona Brock (Quanticate, Hitchin, UK) for conducting the statistical analyses for this paper. The authors would also like to thank Dietmar Pfründer, who was with Pfizer at the time this study was started, for his support during the initial stages of this study.

The study protocol was initiated and developed by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology.

Manuscript preparation

Editorial support was provided by Leigh Prevost and Dominik Wolf of PAREXEL and was funded by Pfizer International Operations.

Potential conflicts of interest

G.M. has served as a consultant for Gilead Sciences, Merck/MSD, and Pfizer, and has been on the speakers’ bureau for Cephalon, Gilead Sciences, Merck/MSD, and Pfizer. W.J.H. has served as a consultant for Merck/MSD and Pfizer, and has been on the speakers’ bureau for Cephalon, Gilead Sciences, Merck/MSD, and Pfizer. B.H. has no conflicts of interest to declare. H.-A.H. has no conflicts of interest to declare. C.R. has no conflicts of interest to declare. T.W. has no conflicts of interest to declare. O.A.C. is supported by the German Federal Ministry of Research and Education (BMBF grant 01KN1106) and has served as a consultant for Astellas, Basilea, F2G, Gilead, Merck/Schering, Optimer, and Pfizer; he has received research grants from Astellas, Basilea, Gilead, Merck/Schering, Optimer, and Pfizer; and lecture honoraria from Astellas, Gilead, Merck/Schering, and Pfizer. J.L. has no conflicts of interest to declare. M.R. has been a paid advisory board member and has received lecture honoraria, including service on speakers’ bureaus, from Essex, MSD, Pfizer, Gilead, Astellas, and Novartis; he has also received research grants/grants pending from Pfizer, MSD, and Deutscher Stifterverband, and payment for the development of educational presentations from Pfizer.

Author information

Authors and Affiliations

  1. Klinikum Ernst von Bergmann, Charlottenstrasse 72, 14467, Potsdam, Germany

    G. Maschmeyer

  2. Universitätsklinikum Würzburg, Würzburg, Germany

    W. J. Heinz & J. Löffler

  3. Klinikum Bremen Mitte, Bremen, Germany

    B. Hertenstein

  4. Universität Kiel, Kiel, Germany

    H.-A. Horst

  5. Universität Erlangen-Nürnberg, Erlangen, Germany

    C. Requadt

  6. Universitätsklinikum Schleswig-Holstein (Campus Lübeck), Lübeck, Germany

    T. Wagner

  7. 1st Department of Internal Medicine; ZKS Köln, BMBF 01KN1106; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany

    O. A. Cornely

  8. Charité Universitätsmedizin (Campus Mitte), Berlin, Germany

    M. Ruhnke

Authors
  1. G. Maschmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. J. Heinz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Hertenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-A. Horst
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Requadt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O. A. Cornely
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Löffler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Ruhnke
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the IDEA study investigators

Corresponding author

Correspondence to G. Maschmeyer.

Additional information

Disclaimer

Voriconazole is not specifically licensed for empirical antifungal therapy in febrile neutropenic patients.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 25 kb)

Appendix

Appendix

In addition to the authors, the following principal investigators participated in the IDEA study: Dr. Walter E. Aulitzky (Robert-Bosch-Krankenhaus, Stuttgart, Germany), Dr. Hartmut Bertz (Medizinische Universitätsklinik und Poliklinik, Freiburg, Germany), Dr. Claudia Binder (Georg-August-Universität, Göttingen, Germany), Dr. Stefanie Buchholz (Medizinische Hochschule Hannover, Hannover, Germany), Dr. Axel A. Fauser (Klinik für KMT und Hämatologie/Onkologie, Idar-Oberstein, Germany), Dr. Mathias Hänel (Klinikum Chemnitz, Chemnitz, Germany), Dr. Wolfgang Heit (Ev. KKH Essen-Werden, Essen, Germany), Dr. Martin Hoffmann (Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany), Dr. Meinolf Karthaus (Klinikum Neuperlach, München, Germany), Dr. Ulrich Keller (Klinikum Rechts der Isar der TU München, München, Germany), Dr. Michael G. Kiehl (Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany), Dr. Wolf-Dieter Ludwig (Helios-Klinikum Berlin Buch, Berlin, Germany), Dr. Rolf Mahlberg (Klinikum Mutterhaus der Borromärinnen, Trier, Germany), Dr. Stefan Neuburger (Charité Universitätsmedizin, Campus Virchow-Klinikum, Berlin, Germany), Dietger Niederwieser (Universitätsklinikum Leipzig, Leipzig, Germany), Dr. Michael Pfreundschuh (Universitätsklinikum des Saarlandes, Homburg/Saar, Germany), Dr. Günther Schlimok (Zentralklinikum Augsburg, Augsburg, Germany), Dr. Norbert Schmitz (AK St. Georg, Hamburg, Germany), Dr. Ulrich S. Schuler (Universitätsklinikum Carl Gustav Carus, Dresden, Germany), Dr. Rainer Schwerdtfeger (Stiftung Deutsche Klinik f. Diagnostik GmbH, Wiesbaden, Germany), Dr. Kambiz Tagizadeh (Evangelisches Johannes-Krankenhaus Bielefeld, Bielefeld, Germany), Dr. Eckhard Thiel (Charité Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany), Dr. Andrew J. Ullmann (Klinikum der Johannes Gutenberg Universität Mainz, Mainz, Germany), Dr. Axel Zander (Universitätskrankenhaus Hamburg-Eppendorf, Hamburg, Germany).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maschmeyer, G., Heinz, W.J., Hertenstein, B. et al. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. Eur J Clin Microbiol Infect Dis 32, 679–689 (2013). https://doi.org/10.1007/s10096-012-1794-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-012-1794-4

Keywords

Search

Navigation